Phase 2 Crohn's Disease and Colitis Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
For people with Crohn's Disease (CD):
- People whose Crohn's Disease symptoms score at a certain level of severity (a score of 220 or higher on a standard measurement tool called the CDAI)
- People who have had a confirmed diagnosis of Crohn's Disease for at least 90 days before the study start date
- People whose bowel inflammation has been confirmed by a camera examination of the gut, reaching a certain score on a standard inflammation scale (confirm with trial site for exact score thresholds)
- People whose Crohn's Disease has not responded well enough to at least one previous treatment
For people with Ulcerative Colitis (UC):
- People who have had a confirmed diagnosis of Ulcerative Colitis for at least 90 days before the study start date
- People with currently active Ulcerative Colitis, confirmed by a standard scoring system measuring symptom severity and gut inflammation at a specific level
- People whose Ulcerative Colitis has not responded well enough to at least one previous treatment
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have had a known bad reaction or intolerance to a group of medicines called p19 IL-23 inhibitors, which includes a drug called risankizumab
- People who have taken part in another clinical trial or received an experimental drug within 30 days (or longer, depending on the drug) before starting this study
- People who have received certain biological or small molecule treatments within a specific time period before the study start date (confirm exact timeframes with trial site)
- People who have had bowel surgery to remove part of their intestine within the 3 months before the study start date
- CD specific: People who have had more than 3 bowel removal surgeries in the past
- CD specific: People who have had sections of small bowel removed that add up to more than 100 cm in total
- UC specific: People who have previously had all or most of their large bowel surgically removed
- UC specific: People whose Ulcerative Colitis affects less than 10 cm of the rectum only
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission; Ulcerative Colitis Specific: Percentage of Participants who Achieve Endoscopic Remission; Number of Participants with Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.